• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $BYSI

    BeyondSpring Inc.

    Subscribe to $BYSI
    $BYSI
    Biotechnology: Pharmaceutical Preparations
    Health Care

    BeyondSpring Inc., a clinical stage biopharmaceutical company, together with its subsidiaries, focuses on the development and commercialization of immuno-oncology cancer therapies. The company's lead asset is the Plinabulin, a selective immune-modulating microtubule-binding agent that has completed Phase III clinical trials for the prevention of chemotherapy-induced neutropenia; and developing Plinabulin, which is in Phase III clinical trial for the treatment of later-stage non-small cell lung cancer (NSCLC). It is also developing Plinabulin in combination with various immuno-oncology agents, including nivolumab, a PD-1 antibody for the treatment of NSCLC; nivolumab and ipilimumab, a CTLA-4 antibody for the treatment of small cell lung cancer; and in combination with PD-1 or PD-L1 antibodies and radiation for the treatment of various cancers. In addition, the company engages in the development of three small molecule immune agents in preclinical stages; and a drug development platform. BeyondSpring Inc. has collaboration agreements with the Fred Hutchinson Cancer Research Center and the University of Washington. The company was founded in 2010 and is headquartered in New York, New York.

    IPO Year: 2017

    Exchange: NASDAQ

    Website: beyondspringpharma.com

    Peers

    $ATNM

    Recent Analyst Ratings for BeyondSpring Inc.

    DatePrice TargetRatingAnalyst
    12/2/2021$38.00 → $5.00Buy → Hold
    Jefferies
    12/2/2021$45.00 → $5.00Buy → Underperform
    B of A Securities
    12/1/2021Outperform → Mkt Perform
    William Blair
    12/1/2021Buy → Neutral
    H.C. Wainwright
    9/20/2021$100.00 → $65.00Buy
    HC Wainwright & Co.
    9/9/2021$50.00Outperform
    Robert W. Baird
    9/9/2021$50.00Outperform
    Baird
    8/4/2021$100.00Neutral → Buy
    HC Wainwright & Co.
    See more ratings

    BeyondSpring Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Kirkby Matthew

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 9:00:36 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Executive Officer Huang Lan

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 9:00:05 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Delaney Brendan

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 8:59:42 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Majeti Jiangwen

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 8:58:46 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Xu Sihai

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 8:58:25 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Fabbio Patrick

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 8:58:04 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Chief Scientific Officer Lu Yingjuan June

      4 - BeyondSpring Inc. (0001677940) (Issuer)

      4/23/25 8:57:35 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Xu Sihai

      3 - BeyondSpring Inc. (0001677940) (Issuer)

      12/31/24 1:34:51 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Majeti Jiangwen claimed ownership of 50,914 units of Ordinary Shares (SEC Form 3)

      3 - BeyondSpring Inc. (0001677940) (Issuer)

      12/31/24 1:34:30 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • New insider Lu Yingjuan June claimed ownership of 100 units of Ordinary Shares (SEC Form 3)

      3 - BeyondSpring Inc. (0001677940) (Issuer)

      12/31/24 1:34:04 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care

    BeyondSpring Inc. Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • BeyondSpring downgraded by Jefferies with a new price target

      Jefferies downgraded BeyondSpring from Buy to Hold and set a new price target of $5.00 from $38.00 previously

      12/2/21 5:17:19 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by B of A Securities with a new price target

      B of A Securities downgraded BeyondSpring from Buy to Underperform and set a new price target of $5.00 from $45.00 previously

      12/2/21 4:49:29 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by William Blair

      William Blair downgraded BeyondSpring from Outperform to Mkt Perform

      12/1/21 10:55:31 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by H.C. Wainwright

      H.C. Wainwright downgraded BeyondSpring from Buy to Neutral

      12/1/21 9:40:22 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on BeyondSpring with a new price target

      HC Wainwright & Co. reiterated coverage of BeyondSpring with a rating of Buy and set a new price target of $65.00 from $100.00 previously

      9/20/21 12:27:04 PM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Robert W. Baird initiated coverage on BeyondSpring with a new price target

      Robert W. Baird initiated coverage of BeyondSpring with a rating of Outperform and set a new price target of $50.00

      9/9/21 7:11:46 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Baird initiated coverage on BeyondSpring with a new price target

      Baird initiated coverage of BeyondSpring with a rating of Outperform and set a new price target of $50.00

      9/9/21 5:19:29 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring upgraded by HC Wainwright & Co. with a new price target

      HC Wainwright & Co. upgraded BeyondSpring from Neutral to Buy and set a new price target of $100.00

      8/4/21 9:07:29 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BeyondSpring downgraded by HC Wainwright & Co.

      HC Wainwright & Co. downgraded BeyondSpring from Buy to Neutral

      4/5/21 6:08:16 AM ET
      $BYSI
      Biotechnology: Pharmaceutical Preparations
      Health Care